Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOPCON treatment effects in fibrodysplasia ossificans progressiva
RBR-9dkn9ryCompleted
- Sponsor
- Universidade Federal de Mato Grosso do Sul
- Start
- Oct 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ascorbic acid, propranolol and hesperidin in fibrodysplasia ossificans progressiva (FOP) (4 arms), sponsored by Universidade Federal de Mato Grosso do Sul. Started Oct 2021; status: completed.
02
Drugs
ascorbic acidpropranololhesperidin
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on RBR-9dkn9ry.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9dkn9ry.